
Conclusions: Response and survival rates of GIFOX in high-risk PTCL compared more than favorably to CHOP-based regimens. Relevant toxicities were G4 thrombocytopenia (13%), G4 anemia (23%), G3/G4 infection (29%/6%), G3 encephalopathy (6%). Estimated 4-yr disease-free survival was 58%. Estimated 5-yr PFS was 48% (95%CI: 28-65) median PFS for non-transplanted pts was 15 mo.s. Twelve pts mobilized SCs (median CD34 ⁺ cells harvest: 4.36x10 ⁶ /kg) and 8 (7CRs,1PR) underwent ASCT, 6 to 13 weeks after the 6th course. Only 5 pts received <4 courses, due to progression (n=4) or early death (n=1). A total of 172 courses was delivered (median 6, r 2-6). Results: Thirty-four pts (median age 63 yrs, r 42-80), with IPI score intermediate-high (62%) or high (38%) were accrued. Simon's minimax two-stage design was adopted with the primary and secondary endpoints of response rate (RR) and progression-free survival (PFS), respectively.

GIFOX ALTERNATIVE FULL
Effective cytoreduction and prompt access to ASCT were ensured, together with safe delivery of a full induction program to transplant-ineligible pts.īackground: Patients (pts) with peripheral T/NK cell lymphomas (PTCL) and intermediate-high/high IPI risk have a 5-yr overall survival 65 yrs), G-CSF DD 7-11] were planned for all pts, with SCs mobilization at course 3 in ASCT-eligible pts.

Twelve pts mobilized SCs (median CD34+ cells harvest: 4.36x106/kg) and 8 (7CRs,1PR) underwent ASCT, 6 to 13 weeks after the 6th course.

Gifox offers the ultimate ease of access with no interruptions to your workflow.Background: Patients (pts) with peripheral T/NK cell lymphomas (PTCL) and intermediate-high/high IPI risk have a 5-yr overall survival 65 yrs), G-CSF DD 7-11] were planned for all pts, with SCs mobilization at course 3 in ASCT-eligible pts. Drag and drop your GIFs whenever you need or get a direct sharing link to any of your creations without switching from what you’re doing.

